Heart Fi-Re · HEART FIne REgulation through mechanosensing in myosin filaments: merging theory and experiments into a multi-scale heart simulator
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2021-07-01 → 2024-09-29
- Финансиране от ЕС
- 276 498 €
- Участници
- 2
- Схема
- MSCA-IF
Линиите свързват координатора с партньорите.
Накратко на български
Механизмите за регулиране на силата на сърдечния мускул се изследват чрез взаимодействието между протеините миозин и актин. Разбирането на тези процеси помага за разработването на терапии при хипертрофична кардиомиопатия.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
HEART FIne REgulation through mechanosensing in myosin filaments: merging theory and experiments into a multi-scale heart simulator
Muscle force is directly proportional to the number of myosin motors going through the so-called cross-bridge cycle, the ATP-driven interaction between myosin proteins, protruding from the thick filament, and actin proteins, forming the thin filament. Classically, the calcium concentrations ([Ca2+]) in the myofibrillar space is known to modulate the activation of the thin filament and, through it, the number of detached but active (ON, pointing toward the thin filament) myosin motors, which generate the cross-bridges. However, in 2010, two detached states have been identified, biochemically defined on the basis of their rate of ATP consumption: a classical disordered relaxed state (DRX) and an unexpected stable state with an ATPase rate of one order of magnitude lower, the super-relaxed state (SRX). This SRX state has also been proposed to be the biochemical counterpart of the structurally defined detached state where motors lie on the thick filament and are unable to interact with activated actin (OFF state). Importantly, ground-breaking data in 2015 have proved the existence of an internal mechano-sensing (MS) mechanism that relates the ratio of ON-to-OFF motors to the tension sustained by the thick myosin filament (Figure 1). Yet the molecular bases of the MS mechanism remain mostly unknown, and this limits the strategies to address cardiac pathologies related to its dysfunction. The MS mechanism creates a critical cellular feedback mechanism, in which malfunction can be at play in hypertrophic cardiomyopathies (HCM). Accordingly, the pharmacological “stabilization” of the OFF state has been shown to prevent or reduce HCM consequences, a therapeutic option that already reached the clinical stage. Then, the MS mechanism play a fundamental role in our basic understanding of the physiological aspects of the skeletal and cardiac muscle contraction, but also it has implications in the treatment of hypertrophic and dilated cardiomyopathies, allowing the developed of a drug for the treatment of HCM that, in essence, is a stabilizer of the OFF state. On these grounds, the project wants to shape the theoretical description of this mechanism and usher it into a multiscale model - from the molecule to the organ. Doing so will enable to create a benchmark to drive pharmacological applications, aiming at reducing the failure rate in this drug discovery pipeline. At its conclusion, the project made a substantial contribution to highlight the differences between the biochemically defined SRX state and structurally defined Off state, and the interconnected mechanism between the thin filament activation and the thick filament activation through a cross-talk mechanism. Moreover, the project shown the need to characterize the diffusion of calcium ions inside the muscle cell, to properly understand the mechanical activation of the thick filament. As a long-term goal reached by the project, a cluster of researchers with complementary expertise has been created at the University of Padova and integrated, as a crucial node, in an international network of collaborations, both within Europe and outside it. The collaboration will foster new results in the aim of personalized medicine.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Multi-scale heart simulators for patient specific treatments are an important challenge for the development of the health system, but require interdisciplinary interaction of several techniques to link experimental observations at the molecular level to the cardiac performance. The mechanosensing (MS) mechanism active in the myosin thick filament, recently discovered, is promising for the understanding of several unresolved questions in muscle field, including the molecular basis of the Frank-Starling law of the heart. MS mechanism finely regulates the number of myosin motors ready to generate force, sensing the tension sustained by the thick filament in any stage of the heart cycle. The mechanism appears to be crucial for the fine regulation of muscle contraction, deserving as a second regulator respect the classical Calcium concentration. However, its theoretical description at present is limited to purely phenomenological models and very few groups in the world are already able to produce clear evidences on it. The present project aims at establishing a collaboration between researchers in this field with complementary theoretical and experimental expertise to quantitatively characterize the MS mechanism at the fibre level through an innovative mathematical model and experimentally validate it with cutting-edge techniques present in the host and partner institutes. The fibre model will be included into a powerful whole heart simulator, to evaluate the macroscopic impact of MS mechanism, and its predicted effects on clinical problems, including its recently discovered relationships with cardiomyopathies. The project will foster an international network of collaborations, where the host institution will be a crucial node. The complimentary knowledges and high excellence of the groups, is a firm foundation on which to build the impact of the project: at my career level, at the institutes level and also at the system level.
Оригинален текст от CORDIS (на английски).
Участници
Връзки
Данни: CORDIS, © Европейски съюз
